ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 279 filers reported holding ACADIA PHARMACEUTICALS INC in Q4 2019. The put-call ratio across all filers is 0.89 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $266,919 | -12.8% | 12,808 | +0.2% | 0.05% | -14.5% |
Q2 2023 | $306,105 | +26.5% | 12,781 | -0.6% | 0.06% | +24.0% |
Q1 2023 | $242,025 | +18.3% | 12,860 | +0.1% | 0.05% | +16.3% |
Q4 2022 | $204,508 | -23.4% | 12,846 | -21.4% | 0.04% | -35.8% |
Q3 2022 | $267,000 | +16.1% | 16,346 | 0.0% | 0.07% | +24.1% |
Q2 2022 | $230,000 | -40.1% | 16,346 | +3.2% | 0.05% | -28.9% |
Q1 2022 | $384,000 | +10.7% | 15,846 | +6.7% | 0.08% | +16.9% |
Q4 2021 | $347,000 | -25.4% | 14,846 | -47.0% | 0.06% | -31.6% |
Q3 2021 | $465,000 | -24.4% | 28,000 | +11.1% | 0.10% | -24.6% |
Q2 2021 | $615,000 | -5.4% | 25,200 | 0.0% | 0.13% | -10.6% |
Q1 2021 | $650,000 | -44.2% | 25,200 | +15.6% | 0.14% | -51.0% |
Q4 2020 | $1,165,000 | +116400.0% | 21,800 | 0.0% | 0.29% | -13.5% |
Q3 2020 | $1,000 | -99.9% | 21,800 | +4.8% | 0.33% | +11.7% |
Q2 2020 | $1,008,000 | +34.8% | 20,800 | +17.5% | 0.30% | +10.8% |
Q1 2020 | $748,000 | +82.0% | 17,700 | +84.4% | 0.27% | +128.0% |
Q4 2019 | $411,000 | – | 9,600 | – | 0.12% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Finepoint Capital LP | 556,553 | $11,598,565 | 5.78% |
Baker Brothers Advisors | 42,864,612 | $893,298,514 | 5.15% |
RTW INVESTMENTS, LP | 11,576,537 | $241,255,031 | 5.09% |
Palo Alto Investors LP | 2,405,793 | $50,136,726 | 4.74% |
Birchview Capital, LP | 240,400 | $5,009,936 | 4.26% |
EcoR1 Capital, LLC | 5,991,479 | $124,862,422 | 4.21% |
EMERALD ADVISERS, LLC | 1,681,052 | $35,033,124 | 1.70% |
EMERALD MUTUAL FUND ADVISERS TRUST | 1,303,988 | $27,175,110 | 1.64% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 179,702 | $3,739,599 | 1.26% |
SECTOR GAMMA AS | 179,785 | $3,746,719 | 0.96% |